Safety of Stool Transplant for Patients With Difficult to Treat C. Difficile Infection
Safety of Stool Transplant for Patients With Difficult to Treat C. Difficile Infection
The purpose of this study is to test the safety of FMT in patients with C. difficile and
 cancer. In previous other studies, FMT has been shown to cure C. difficile when antibiotics
 have failed, but most of these studies have not included patients with cancer. The
 investigators want to prove that FMT is safe in this group of people so that doctors will
 feel more comfortable prescribing it for their patients with cancer.
Inclusion Criteria:

 -  ≥18 years old

 -  Patients with solid organ malignancy who have received chemotherapy within the past
 six months.

 -  Clinical and microbiologic relapse of C. difficile associated diarrhea after at least
 one course of adequate antibiotic therapy or refractory disease that does not respond
 to treatment.

 -  At least 10 days of vancomycin at least 125mg QID, or metronidazole 500mg TID

 -  C. difficile associated diarrhea is defined as: ≥3 loose or watery stools per day
 for at least 2 consecutive days or ≥8 loose stools in 48 hours and Positive
 Clostridium difficile PCR

 -  Life expectancy of >3 months.

 Exclusion Criteria:

 -  Expected prolonged compromised immunity

 -  HIV infection with CD4 count <240

 -  History of hematopoietic stem cell transplant (HSCT)

 -  Hematologic malignancy

 -  ANC <1000/mm3

 -  Contraindications to anesthesia for procedure

 -  Serious cardiopulmonary comorbidities

 -  Inability to tolerate anesthesia

 -  HGB <8 g/dL

 -  Risk of bleeding during procedure

 -  PLT <50,000 K/mcL

 -  INR >1.5 INR

 -  Pregnancy

 o Pregnant patients will be excluded from this study.

 -  Gastrointestinal (GI) contraindications

 -  Inflammatory bowel disease

 -  Active fistula

 -  Small bowel obstruction

 -  Ileus

 -  Gastroparesis

 -  Nausea and vomiting

 -  Gastrointestinal surgery within the previous 3 months